A seven-point calibration curve with a five parameter

logistical curve fitting was used (BioPlex Manager 6.0, BioRad UK). The calibration material was generated by mixing an equal amount of the stock κ and λ FLC material, and then diluting this 1 in 8 in FLC buffer to give the starting calibration point (437.5 mg/L). The top calibrator was then serially diluted 4-fold in FLC buffer to 0.1 mg/L, in duplicate. In-house quality controls were used on all assay plates to monitor assay performance and reproducibility. Following incubation for 30 min, filter plates were washed three times using assay buffer and aspirated using a manifold pump. 50 μl streptavidin-PE (diluted 1 in 500 in assay buffer) was added to all wells and incubated for 30 min. After further washing, plates were analysed on a Luminex®

100 system (Luminex Corp., USA). A minimum of 100 STA-9090 solubility dmso beads per bead region, per well of the filter plate, were counted on the Luminex®. Samples exhibiting a high FLC concentration above the initial working range of the calibration curve at a 1 in 5 dilution, were repeated at a 1 in 100 dilution in assay buffer, to avoid extrapolation and ensure reliable quantitation of samples on the linear sectors of the standard curves (see Fig. 1 for representative calibration curves). To establish if each anti-κ FLC mAb provided a similar quantitation of polyclonal κ FLC, and each anti-λ FLC mAb provided a similar quantitation of polyclonal λ FLC, an initial method comparison of each mAb was conducted using 249 donor plasma samples Pexidartinib from the UK NHSBT. From this process, it became clear that each anti-κ FLC mAb provided different results for polyclonal FLC, and subsequent analyses found that each provided different results to Freelite™; the same was found for each anti-λ FLC mAb (data not shown). Hence, it was necessary to use different calibration coefficients for each mAb to provide similar quantitation of polyclonal FLCs to each other, and to Freelite™. Final calibration coefficients were derived by a method comparison (Krouwer et al., 2010)

to the Freelite™ assay for polyclonal FLC (Katzmann et al., 2002). Calibration traceability to Freelite™ was preferred because there is no recognised international standard for FLC, and to ensure that the guidelines issued by the International Working Group 4��8C on Multiple Myeloma (Dispenzieri et al., 2009) are transferable to the mAb assay, as discussed elsewhere (te Velthuis et al., 2011). Accordingly, a calibration coefficient was applied to the calibrator material result obtained by spectrophotometry for κ FLC (437.5 mg/L) and λ FLC (437.5 mg/L). For each anti-FLC mAb, the following calibration coefficients were applied to the calibrator material: BUCIS 01 = 0.731X, BUCIS 04 = 3.086X, BUCIS 03 = 0.869X, BUCIS 09 = 1.600X; where X is equal to the calibrator result by spectrophotometry. Representative calibration curves are displayed in Fig. 1.